Further support for a higher target level comes from a post-hoc analysis of ERC Phase 3 trials, which suggested that mean 25(OH)D levels of ≥ 50.8 ng/mL are required for reductions in PTH and bone turnover markers in CKD stage G3–G4 [60]. Here, PTH is linked to chronic kidney disease.